Healthcare · NSE/BSE: LAURUSLABS
Laurus Labs Limited
Pharmaceuticals
Market Cap ₹0.75L Cr
Verdict: Average
Quality Scores
Multi-Bagger
74/100
Compounder Quality
78/100
Management Credibility
75/100
Governance
88/100
Cash Flow Quality
72/100
AI Summary
Laurus Labs is a vertically integrated pharmaceutical powerhouse that has evolved from an ARV API specialist into a diversified CDMO and Dosage Form player. While the company exhibited explosive growth during the FY21-23 period driven by pandemic-related demand and strategic positioning, FY24-25 has seen a sharp normalization and margin compression due to pricing pressures and high operating leverage. The long-term thesis rests on its massive capacity expansion and pivot towards high-margin CDMO services, which currently account for nearly half of revenue. However, the current high P/E…
Top Opportunities
- Global leadership in Anti-Retroviral (ARV) APIs
- Diversification into high-margin CDMO services
- Strong historical 10-year PAT CAGR of 21%
Top Risks
- Heavy reliance on ARV segment which is price sensitive
- Drastic fall in ROCE from 40% (FY21) to 7% (FY24)
- Sky-high inventory days (crossing 300 days in projections)
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.